ITC shares in focus after Rs 472 crore acquisition of Sresta Natural Bioproducts
ITC's shares are set to be in focus following the completion of its acquisition of Sresta Natural Bioproducts for up to Rs 472.5 crore. This acquisition, finalized on June 13, 2025, makes SNBPL a wholly-owned subsidiary and strengthens ITC's presence in the growing organic food sector, both domestically and internationally, with SNBPL's established network of farmers and certified organic farmland.
Tired of too many ads?
Remove Ads
Tired of too many ads?
Remove Ads
Shares of ITC are likely to be in focus on Monday, June 16, 2025, after the company announced the completion of its acquisition of Sresta Natural Bioproducts Private Ltd (SNBPL) for a total consideration of up to Rs 472.5 crore.According to the company's filing, ITC has acquired the entire share capital of SNBPL, comprising 1,87,48,858 equity shares of Rs 10 each. The acquisition was made for an upfront cash consideration of Rs 400 crore on a cash-free, debt-free basis, subject to customary adjustments.Additionally, ITC may pay up to Rs 72.5 crore over the next 24 months, contingent on specific terms outlined in the Share Purchase Agreement.With this transaction, SNBPL has become a wholly owned subsidiary of ITC. Furthermore, SNBPL's overseas subsidiaries—Fyve Elements LLC (USA) and Sresta Global FZE (UAE)—have now become step-down wholly owned subsidiaries of ITC, effective June 13, 2025.The transaction was concluded on June 13, 2025, the company stated.SNBPL is primarily engaged in the manufacturing and sale of organic food products under the brand '24 Mantra Organic'. The company operates across India and has developed a substantial organic value chain.It has a network of approximately 27,500 farmers and manages around 1.4 lakh acres of certified organic farmland spread across 71 clusters in 10 Indian states. In addition to its domestic market, SNBPL also has a presence in the US with its own distribution infrastructure.Founded on March 9, 2004, SNBPL has consistently reported a consolidated turnover of over Rs 300 crore in each of the last three financial years. For FY2023–24, the company posted a turnover of Rs 306.1 crore, compared to Rs 327.3 crore in FY2022–23 and Rs 326.7 crore in FY2021–22.ITC stated in its disclosure that the acquisition aligns with the company's strategy to augment its future-ready portfolio. The move is expected to strengthen ITC's presence in the high-growth organic products segment, both in India and international markets.The company also highlighted that the domestic organic food products sector holds significant growth potential, driven by increasing health consciousness, rising household incomes, and the growing reach of modern trade and e-commerce channels. ITC shares closed 1.7% lower at Rs 413.90 on the BSE on Friday.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
News18
32 minutes ago
- News18
Influx Healthtech IPO Allotment: A Step-By-Step Guide To Check Status Online Today, Know Latest GMP
Last Updated: According to market observers, the GMP of the Influx Healthtech IPO is 22.92%, indicating decent listing gains for investors. Influx Healthtech IPO Allotment: The initial public offering of Influx Healthtech has received a whopping 201.35 times subscription, indicating huge interest from investors. Investors are now eagerly awaiting its allotment even its latest GMP shows a strong 22.92% listing gains. The allotment of the Influx Healthtech IPO is expected to be finalised today, Monday, June 23, in the evening. Once the IPO allotment is finalised, investors will start receiving bank debit messages, most probably in the evening. They can also check their allotment status on the websites of the NSE as well as registrar Maashitla Securities Private Limited. The allotment is expected to be finalised in the evening today, Friday, June 20. The allotment status can be checked by following these steps: Step 1: Visit Maashitla Securities' portal — Step 2: Under 'Select Company', choose 'Influx Healthtech Ltd'. Importantly, if the company's name is not visible in the drop-down list, it means the allotment has not been finalised yet. According to market observers, the GMP of the Influx Healthtech IPO is 22.92%, indicating decent listing gains for investors. The GMP is based on market sentiments and keeps changing. 'Grey market premium' indicates investors' readiness to pay more than the issue price. Influx Healthtech IPO Listing Date The shares of Influx Healthtech Ltd will be listed on the NSE Emerge on June 25. The Influx Healthtech IPO was open for subscription between June 18 and June 20. It is a book-built issue worth Rs 58.57 crore, comprising a fresh issue of 50 lakh equity shares worth Rs 48 crore and an offer for sale of 11 lakh shares aggregating to Rs 10.56 crore. On the final day of bidding on Friday, the SME IPO received an overwhelming 201.35 times subscription, garnering bids for 81,71,71,200 shares as against 40,58,400 shares on offer. The retail and NII participation stood at 117.68 times and 481.10 times, respectively. Its qualified institutional buyer (QIB) category got a 137.87 times subscription. The price of the Influx Healthtech IPO was fixed at Rs 96 apiece. Influx Healthtech Ltd's revenue increased 5% and its profit after tax (PAT) rose 19% between the financial year ending with March 31, 2025, and March 31, 2024. Rarever Financial Advisors Pvt Ltd is the book-running lead manager of the Influx Healthtech IPO, while Maashitla Securities Private Limited is the registrar for the issue. The market maker for Influx Healthtech IPO is R K Stock Holding Private Limited. Influx Healthtech Ltd, founded in September 2020, is a healthcare-focused CDMO with three manufacturing units in Thane, producing tablets, capsules, powders, liquid orals, and softgels.
Mint
35 minutes ago
- Mint
Israel-Iran war: DMart to Eicher Motors— Jigar Patel of Anand Rathi recommends 3 stocks to buy for the short term
Stocks to buy for the short term: Indian stock market benchmarks, the Sensex and the Nifty 50, crashed over a per cent each in intraday trade on Monday, June 23, as Israel-Iran war escalates further, crude oil prices rise sharply and investors dump riskier equities and rush to safe haven assets. As it is difficult to predict the trajectory of the stock market amid rapidly changing geopolitical scenarios, Jigar S. Patel, Senior Manager of Equity Research at Anand Rathi Share and Stock Brokers, advises traders to remain vigilant. "A decisive breakout above 25,300 could pave the way for a sustained rally toward 25,500–25,600. Conversely, any faltering near current levels could signal renewed caution. On the downside, immediate support lies at 24,700, with a stronger floor near 24,450. Until confirmation is evident, restraint remains prudent near resistance zones," said Patel. Jigar Patel recommends buying shares of DMart, Eicher Motors and Biocon for the next two to three weeks. Over the past month, Eicher Motors has witnessed a healthy correction of approximately 12 per cent from its recent peak of ₹ 5,906. Notably, the stock has established a firm base over the last 15 trading sessions, consolidating between its 50- and 100-day exponential moving averages — a sign of stabilizing price action. In the latest session, Eicher decisively broke out of a dual descending trendline, supported by a steadily improving Relative Strength Index (RSI), which has consistently held above the 40 mark and now stands at 61.42. "The confluence of favourable technical indicators positions Eicher as an attractive long candidate. Traders may consider initiating positions in the ₹ 5,530–5,480 range, targeting ₹ 5,900, with a stop loss placed below ₹ 5,300," said Patel. Eicher Motors Following a steep decline from its recent high of ₹ 4,557, DMart has entered a consolidation phase, forming a strong base around the confluence of its 50-, 100-, and 200-day exponential moving averages (DEMA). Notably, the stock has triggered a bullish golden crossover, with the 50-DEMA moving above the 200-DEMA — a technically significant development often interpreted as a precursor to upward momentum. Adding weight to the bullish bias, the stock has also broken out of a descending trendline, indicating a potential trend reversal. "Given this confluence of positive technical signals, traders may consider initiating long positions in the ₹ 4,300–4,250 zone, with an upside potential toward ₹ 4,700. A stop loss should be maintained below ₹ 4,100 on a daily closing basis," Patel said. DMart Biocon has recently established a robust base around the confluence of its 50-, 100-, and 200-day exponential moving averages (DEMA), signalling price stability after a period of consolidation. A golden crossover — with the 50-DEMA crossing above the 200-DEMA — further reinforces the emerging bullish sentiment. On June 19, 2025, the stock also formed a bullish harami candlestick pattern, accompanied by a close above the R3 Camarilla monthly pivot, strengthening the technical outlook. This alignment of key indicators suggests a potential upside move. "Traders may consider initiating long positions in the ₹ 353–348 range, with a projected target of ₹ 385. A protective stop loss should be placed below ₹ 332 on a daily closing basis to manage risk effectively," said Patel. Biocon Read all market-related news here Disclaimer: This story is for educational purposes only. The views and recommendations above are those of individual analysts or broking companies, not Mint. We advise investors to check with certified experts before making any investment decisions, as market conditions can change rapidly, and circumstances may vary.
India.com
35 minutes ago
- India.com
Good news for Anil Ambani, another company settles Rs 2730000000 loan of…, with…
Anil Ambani was already in the news for settling down the debt of his many companies. Now once again it has settled the debt with another company. In a recent exchange filing it stated that it has fully settled a Rs 273-crore loan, including interest, owed by its wholly owned subsidiary JR Toll Road Pvt Ltd (JRTR) to Yes Bank Ltd. It stated, '' A wholly owned subsidiary of the Company (along with the Company as Corporate Guarantor), has entered into an addendum to the Settlement Agreement today with Yes Bank Limited (YBL) for the entire outstanding debt obligation of ~INR 273 crore (including interest) owed by JRTR to YBL, and has duly paid the entire settlement amount.'' Anil Ambani Company Debt Reduction Debt reduction has become a primary focus for Anil Ambani. Reliance Infrastructure: Paid off Rs 3,300 crore of debt in FY 2025, becoming debt-free. Rosa Power Supply Company: Cleared Rs 485 crore of debt, achieving debt-free status. Reliance Power: Settled a loan of Rs 3,872 crore earlier. JR Toll Road Pvt Ltd, a special purpose vehicle established by Reliance Infrastructure, is responsible for the development, operation, and maintenance of a 52-kilometer segment of National Highway 11, connecting Jaipur and Reengus in Rajasthan. The project was executed under the Design-Build-Finance-Operate-Transfer (DBFOT) model, featuring a highway expansion from four to six lanes. Operations commenced in 2013, coinciding with the start of toll collection.
